Another important pathway able to enhance FXR activity is the release of growth factor FGF-19 from the intestine upon bile acid binding to FXR, documenting favorable effects in in animal NASH models [97]. Here, FGF19 is linked to metabolic dysfunction-associated steatohepatitis.